Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL

Leukemia. 2023 Jan;37(1):222-225. doi: 10.1038/s41375-022-01770-3. Epub 2022 Dec 8.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Bispecific* / therapeutic use
  • Child
  • Disease-Free Survival
  • Humans
  • Neoplasm Recurrence, Local / drug therapy
  • Neoplasm, Residual / drug therapy
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy
  • Recurrence
  • Remission Induction

Substances

  • blinatumomab
  • Antibodies, Bispecific